Trials / Completed
CompletedNCT04923347
A Study to Evaluate the Safety and Efficacy of Fluticasone Furoate (FF)/Umeclidinium(UMEC)/Vilanterol (VI) in Participants With Chronic Obstructive Pulmonary Disease (COPD)
Phase IV, 12-week, Single Arm, Open Label Study Evaluating the Safety and Efficacy of Fixed Dose Triple Combination FF/UMEC/VI Administered Once Daily in the Morning Via a Dry Powder Inhaler in Participants With Chronic Obstructive Pulmonary Disease in India
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 229 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate safety and efficacy of FF/UMEC/VI via ELLIPTA® inhaler. ELLIPTA is a registered trademark of GlaxoSmithKline group of companies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | FF/UMEC/VI | FF/UMEC/VI will be administered |
| DEVICE | ELLIPTA | Participants will receive FF/UMEC/VI using ELLIPTA inhaler. |
Timeline
- Start date
- 2023-06-06
- Primary completion
- 2024-03-14
- Completion
- 2024-03-14
- First posted
- 2021-06-11
- Last updated
- 2025-03-24
- Results posted
- 2025-03-24
Locations
14 sites across 1 country: India
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04923347. Inclusion in this directory is not an endorsement.